The ubiquitously expressed reduced folate carrier (RFC) is the major transport system for folate cofactors in mammalian cells and tissues. Previous considerations of RFC structure and mechanism were based on the notion that RFC monomers were sufficient to mediate transport of folate and antifolate substrates. The present study examines the possibility that human RFC (hRFC) exists as higher order homo-oligomers. By chemical cross-linking, transiently expressed hRFC in hRFC-null HeLa (R5) cells with the homobifunctional cross-linker 1,3-propanediyl bis-methanethiosulfonate and Western blotting, hRFC species with molecular masses of hRFC homo-oligomers were identified. Hemagglutinin-and Myc epitope-tagged hRFC proteins expressed in R5 cells were co-immunoprecipitated from both membrane particulate and surface-enriched membrane fractions, indicating that oligomeric hRFC is expressed at the cell surface. By co-expression of wild type and inactive mutant S138C hRFCs, combined with surface biotinylation and confocal microscopy, a dominant-negative phenotype was demonstrated involving greatly decreased cell surface expression of both mutant and wild type carrier caused by impaired intracellular trafficking. For another hRFC mutant (R373A), expression of oligomeric wild type-mutant hRFC was accompanied by a significant and disproportionate loss of wild type activity unrelated to the level of surface carrier. Collectively, our results demonstrate the existence of hRFC homo-oligomers. They also establish the likely importance of these higher order hRFC structures to intracellular trafficking and carrier function.
Folates are members of the B class of vitamins that are required for the synthesis of nucleotide precursors, serine, and methionine in one-carbon transfer reactions (1) . Because mammals cannot synthesize folates de novo, cellular uptake of these derivatives is essential for cell growth and tissue regeneration (2, 3) . Folates are hydrophilic anionic molecules that do not cross biological membranes by diffusion alone, so it is not surprising that sophisticated membrane transport systems have evolved to facilitate their accumulation by mammalian cells.
The ubiquitously expressed reduced folate carrier (RFC) 2 is widely considered to be the major transport system for folate co-factors in mammalian cells and tissues (3, 4) . RFC plays a generalized role in folate transport and provides specialized tissue functions such as transport across the basolateral membrane of renal proximal tubules (5) , transplacental transport of folates (6) , and folate transport across the blood-brain barrier (7) , although the contribution of RFC to intestinal absorption of folates remains controversial (8, 9) . Loss of RFC expression or function portends potentially profound physiologic and developmental consequences associated with folate deficiency (10) . RFC is also a major transporter of antifolate drugs used for cancer chemotherapy such as methotrexate (Mtx), pemetrexed, and raltitrexed (4) . Loss of RFC expression or synthesis of mutant RFC protein in tumor cells results in antifolate resistance caused by incomplete inhibition of cellular enzyme targets and low levels of antifolate substrate for polyglutamate synthesis (4, 11) .
Reflecting its particular physiologic and pharmacologic importance, interest in RFC structure and function has been high. Since 1994, when murine RFC was first cloned (12) , application of state-of-the-art molecular biology and biochemistry methods for characterizing polytopic membrane proteins has led to a progressively detailed picture of the molecular structure of the carrier, including its membrane topology, N-glycosylation, functionally or structurally important domains and amino acids, and packing of ␣-helix transmembrane domains (TMDs) (4, 13) . Although no crystal structure for RFC has yet been reported, a detailed homology model for human RFC (hRFC) based on the bacterial lactose/proton symporter LacY and glycerol 3-phosphate/inorganic phosphate antiporter GlpT was generated (13, 14) that permits testing of hypotheses related to hRFC structure and mechanism in a manner not previously possible.
Considerations of hRFC structure and mechanism to date have all been based on the notion that a single 591-amino acid hRFC molecule is sufficient to mediate concentrative uptake of folate and antifolate substrates. However, a growing literature suggests that quaternary structure involving the formation of higher order oligomers (e.g. dimers, tetramers, etc.) is commonly an important feature of the structure and function of * This work was supported, in whole or in part, by National Institutes of Health Grant CA53535. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence should be addressed: 110 E. Warren Ave., Detroit, MI 48201. many membrane transporters (15) (16) (17) (18) . For major facilitator superfamily proteins, both monomeric (e.g. LacY, GlpT, UhpT, and GLUT3) (19 -22) and oligomeric (e.g. LacS, AE1, GLUT1, and TetA) (23-28) structures have been reported, establishing the lack of a clear structural consensus for these related proteins.
In this report, we explore the question of whether hRFC exists as a homo-oligomeric species composed of multiple hRFC monomers. Based on results with an assortment of biochemical methods with wt and a collection of mutant hRFC proteins, we not only demonstrate the existence of oligomeric hRFC but also establish the probable importance of these higher order structures to intracellular trafficking and carrier function.
EXPERIMENTAL PROCEDURES

Reagents-[3Ј,5Ј,7-
3 H]Mtx (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). Unlabeled Mtx was provided by the Drug Development Branch, NCI, National Institutes of Health (Bethesda, MD). Both labeled and unlabeled Mtx were purified by high pressure liquid chromatography prior to use (33) . Synthetic oligonucleotides were obtained from Invitrogen. Tissue culture reagents and supplies were purchased from assorted vendors with the exception of fetal bovine serum, which was purchased from Hyclone Technologies (Logan, UT). The cross-linking reagent, MTS-3-MTS (1,3-propanediyl bis-methanethiosulfonate), was purchased from Toronto Research Chemicals (Toronto, Canada).
Generation of hRFC wt and Mutant Constructs-Full-length wt hRFC
Myc-His10 was prepared by PCR from the full-length hRFC (pC43) (34) , using the P6 primer (35) and the antisense FL His 10 /AS primer (5Ј-cgctcgagGGATCCctggttcacattctg-3Ј). PCR conditions were 4 min at 95°C for one cycle, followed by 35 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. The amplicon was digested with BamHI and SfiI (New England Biolabs, Ipswich, MA) and ligated into BamHI/SfiI-digested truncated hRFC Myc-His10 in pCDNA3 (35) . Deglycosylated fulllength hRFC Myc-His10 (dghRFC ) with Gln substituted for Asn at position 58 was generated by site-directed mutagenesis with the QuikChange TM kit (Stratagene, La Jolla, CA), using the wt hRFC Myc-His10 construct as template. The same strategy was used with full-length wt hRFC HA template (36) to generate the S138C-hRFC HA , G163P-hRFC HA , and R373A-hRFC HA mutants. Mutation primers were designed on the Stratagene web site. Sequences for the mutation primers are available upon request. All of the mutations were confirmed by automated DNA sequencing at the Wayne State University Sequencing Core.
Cell Culture-hRFC-null Mtx-resistant HeLa cells, designated R5 (37) , were a gift of Dr. I. David Goldman (Bronx, New York). R5 cells were maintained as previously reported (38) . wt and mutant hRFC constructs (see above) were transfected into R5 cells with Lipofectamine Plus reagent (Invitrogen) (38) . For experiments in which transfections with two plasmid constructs were compared with results for cells trans- fected with a single plasmid construct, total DNA for the latter was maintained constant by adding empty pCDNA3. Myc-His10 were washed with ice-cold Dulbecco's phosphate-buffered saline (PBS) twice and then treated with MTS-3-MTS (5 Å, flexible) at a final concentration of 0.05 mM for 30 min at 4°C. An equivalent amount of dimethylformamide (solvent used for MTS-3-MTS) was added to the transfected cells as a negative control. The reactions were terminated by the addition of 5 mM N-ethylmaleimide. After washing with ice-cold PBS (twice), treated cells were harvested and stored at Ϫ20°C. Plasma membrane preparations were prepared by differential centrifugation (39) , and samples (3.3 g protein) were treated with dithiothreitol (DTT) (0°C; 0 -2.5 mM) and analyzed by SDS-PAGE and Western blotting (see below).
Membrane Transport Experiments-Cellular uptake of [ 3 H]Mtx (0.5 M) was measured over 2 min at 37°C in 60-mm dishes in Hepes-sucrose-Mg ϩ2 buffer (20 mM Hepes, 235 mM sucrose, pH adjusted to 7.3 with MgO), as described previously (38) . The levels of intracellular radioactivity were expressed as pmol/mg of protein, calculated from direct measurements of radioactivity and protein contents (40) of the cell homogenates.
Immunoprecipitation Protocol-Immunoprecipitations were performed as described previously (38) , using mouse anti-Myc and mouse anti-hemagglutinin (HA) monoclonal antibodies (Covance, Emeryville, CA). The samples were eluted with 3ϫ SDS-PAGE sample buffer (41) and fractionated on a 7.5% polyacrylamide gel in the presence of SDS for Western blotting.
Membrane Preparations, SDS-PAGE, and Western Blot Analysis-
Plasma membrane preparation, SDS-PAGE, and electrotransfer to polyvinylidene difluoride membranes (Pierce) were performed exactly as reported previously (38) . Detection and quantitation of immunoreactive proteins was with anti-myc anti-HA antibody and IRDye800-conjugated secondary antibody with an Odyssey Infrared Imaging System. Densitometry used the Odyssey software (v 1.2). To quantitate the broadly banding hRFC forms, identical areas were "boxed" and corrected for background (i.e. an identical boxed "blank" region). Linearity was established over a 20-fold range of hRFC expression. 
Surface Labeling with Sulfo-N-hydroxysuccinimide (NHS)-SS-biotin-The
Cell Surface Labeling Accessory Pack (Thermo Scientific, Rockford, IL) was used to label and isolate surface proteins. Briefly, the cells were incubated with 0.25 mg/ml sulfo-NHS-SS-biotin in PBS for 30 min at 4°C and then solubilized with lysis buffer. The lysate was centrifuged to remove the insoluble fraction. The supernatant was incubated with immobilized NeutrAvidin TM gel slurry for 1 h at room temperature, and the beads were then washed five times with wash buffer containing protease inhibitors (Roche Applied Science). The proteins were eluted with 1ϫ SDS-PAGE sample buffer (41) containing 50 mM DTT and analyzed by SDS-PAGE/ Western blotting. For immunoprecipitations, surface labeled proteins were eluted with Buffer A (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate) (38) , which was then used for immunoprecipitation (see above) but in the presence of 50 mM DTT.
Confocal ) transfections were performed, as described above. After 48 h, the cells were fixed with 3.3% paraformaldehyde (in PBS), permeabilized with 0.1% Triton X-100 (in PBS), and stained with primary antibodies, followed by incubation with secondary antibodies, as previously described (35) . The primary antibodies used were mouse anti-Myc and mouse anti-HA monoclonal antibodies (Covance) and rabbit antiMyc and goat anti-HA polyclonal antibodies (Abcam, Cambridge, MA). A variety of fluorescent secondary antibodies were used, including Alexa Fluor 350 donkey anti-goat IgG (HϩL), Alexa Fluor 568 donkey anti-rabbit IgG (HϩL), Alexa Fluor 568 donkey anti-goat IgG (HϩL), and Alexa Fluor 488 donkey anti-mouse IgG (HϩL) (Molecular Probes, Eugene, OR). To stain the ER, the SelectFX Alexa Fluor 488 endoplasmic reticulum labeling kit (Molecular Probes) was used. Cross-reactivities between primary antibodies (anti-Myc and anti-HA) and between secondary antibodies were also tested. The slides were visualized with a Zeiss laser scanning microscope 510 using a 63ϫ water immersion lens, using the same parameter setting for all of the samples. Confocal analysis was performed at the Imaging Core of the Karmanos Cancer Institute.
RESULTS AND DISCUSSION
Identification of Higher Order hRFC Structures by Crosslinking-Chemical cross-linking is a powerful method for establishing proximities of proteins in their native state (42) and has been extensively used to study quaternary structures of membrane proteins (15 (Fig.  1) . To explore the possibility that hRFC may exist as a higher order oligomer, we used an intermediate length (5 Å) methane thiosulfonate bifunctional cross-linker, MTS-3-MTS, capable of cross-linking nearby Cys residues, to treat hRFC-null R5 HeLa cells transfected with a hRFC construct epitope-tagged with a Myc-His 10 linked to position 591 and in which the N-glycosylation consensus site at position 58 was mutated to Gln (dghRFC Myc-His10 ). Following cross-linking at 4°C, plasma membranes were prepared, and the membrane proteins were analyzed by SDS-PAGE (under nonreducing conditions) and Western blotting with Myc-specific antibody. Our rationale for using dghRFC Myc-His10 for these experiments involved the need to estimate the sizes of potential cross-linked hRFC species without complications of N-glycosylation and was based on our previous finding that mutation of Asn 58 to Gln had only very modest effects on hRFC surface expression and transport function (43) . As shown in lieu of cross-linker, for which only monomeric dghRFC (ϳ69 kDa; labeled a, lane 1) was detected. The most prominent cross-linked band (Fig. 2, lane 2, band b) migrated at ϳ140 kDa. Bands c and d exhibited estimated molecular masses of ϳ160 and ϳ210 kDa, respectively, whereas band e migrated as a larger species (Ͼ250 kDa). Treatment of crosslinked membranes with DTT (1.25 and 2.5 mM) prior to SDS-PAGE, reversed cross-linking for bands b, d, and e, as reflected in their disappearance (Fig. 2, lanes 3 and 4) . However, band c was unaffected, suggesting that it arose as nonspecific aggregation product of hRFC in which bonds formed between MTS-3-MTS and Cys are inaccessible to DTT. Although the origin of bands b, d, and e could conceivably involve cross-linking of dghRFC Myc-His10 with non-hRFC proteins, the sizes of these bands approximate those for predicted masses of dimeric, trimeric, and possibly tetrameric dghRFC Myc-His10 , suggesting that they represent homo-oligomers of hRFC. Most importantly, these results establish the feasibility of the existence of homo-oligomeric hRFC. To further confirm the existence of cell surface oligomeric hRFC, a parallel experiment was performed in which R5 cells were co-transfected with wt hRFC HA and wt hRF-C Myc-His10 and then treated with sulfo-NHS-SS-biotin, which biotinylates hRFC molecules at the cell surface via accessible amine groups. Cells so treated were lysed, and biotinylated proteins were bound to strepavidin-agarose (NeutrAvidin TM ) and then eluted with buffer A containing 50 mM DTT. The eluates were immunoprecipitated with Myc antibody in parallel with a membrane particulate fraction from the same transfection (prepared by differential centrifugation) (39) and analyzed by SDS-PAGE and Western blotting with HA-and Myc-specific antibodies. Fig. 3B shows that identical results were obtained for particulate (lane 1) and biotinylated (lane 2) Myc-and HA-tagged wt hRFCs. This indicates that hRFC associates with hRFC HA at the membrane surface. These results establish that hRFC exists as a higher order homo-oligomer between hRFC monomers at the plasma membrane surface.
Dominant-negative Associations between wt and Mutant hRFC Monomers-One approach for establishing the functional consequences of oligomerization of transporter proteins involves co-expression of active and inactive carriers (23, 44 -46) . By this approach, the presence of a nonfunctional Myc-His10 as mean values plus/minus standard errors from three independent experiments. Transport activities that were significantly different (p ϭ 0.05 paired t test) from that for wt hRFC Myc-His10 are noted with asterisks. In B, the results are shown for surface hRFC proteins labeled with sulfo-NHS-SS-biotin and measured by SDS-PAGE and Western blotting. Na ϩ K ϩ ATPase was used as a loading control (mouse antibody from Novus Biologicals, Littleton, CO). Relative levels of wt and mutant hRFC proteins for a representative experiment were measured by densitometry and are noted below each lane. In replicate experiments, densitometry values did not vary more than 10%. The Myc-and HA-tagged hRFC constructs used for each transfection are indicated. The molecular mass markers for SDS-PAGE are noted. mutant will not adversely affect the activity of a wt transporter that is functional as a monomer (46) . However, if two or more monomers form the active transporter, the presence of a nonfunctional mutant could decrease overall transport activity.
As an extension of our earlier studies of Cys insertion mutants for hRFC (14) , we identified three hRFC mutants with significant losses of transport activity (Յ6% of wt) associated with decreased hRFC levels (S138C and G163P; ϳ20 and ϳ50%, respectively, of wt) or replacement of a functionally important amino acid without changes in expression (R373A) (positions of the mutants are shown in the hRFC schematic in Fig. 1 ; transport and Westerns are shown in Fig. 4) .
We co-transfected R5 HeLa cells with wt hRFC
Myc-His10 and HAtagged wt or mutant hRFCs, for comparison with singly transfected R5 cells. After 48 h, the cells were assayed for [ 3 H]Mtx transport, correlating with levels of cell surface hRFC forms by sulfo-NHS-SS-biotin labeling (Fig. 5) . The single S138C-, G163P-, and R373A-hRFC HA transfectants exhibited the expected transport/cell surface expression phenotypes. Although all of the mutants were expressed at the plasma membrane surface (in variable levels), from its aberrant migration on SDS-PAGE, S138C appeared to be less glycosylated than either G163P or R373A-hRFC (Fig. 5B) .
wt hRFC (Myc-tagged, with or without HA-tagged wt hRFC) exhibited transport closely approximating hRFC cDNA "dosage" (i.e. 1ϫ versus 2ϫ) and cell surface expression. Mtx transport was significantly decreased for all three wt/mutant co-transfections, ranging from 28% of wt (Myc) for S138C-hRFC to 49 and 63% of wt (Myc) for G163P-and R373A-hRFC, respectively (Fig. 5A) . Co-transfections with wt hRFC Myc-His10 had no obvious impact on surface expression levels for S138C-and G163P-hRFC HA from those in cells singly transfected with mutant hRFCs. However, losses of wt transport activity in the presence of the S138C and G163P mutants were accompanied by dramatic losses of surface wt hRFC Myc-His10 protein (ϳ15 and ϳ61% of the level for wt hRFC Myc-His10 co-expressed with wt hRFC HA ) (Fig. 5B) . This was not explained by differences in transfection efficiencies (based on co-transfections with a luciferase reporter construct; data not shown). There were no significant differences in the levels of either wt hRFC Myc-His10 or R373A-hRFC HA between the double and singly transfected R5 cells. Despite these striking variations in surface carrier levels and transport function for the different wt/mutant hRFC combinations, by co-immunoprecipitations of biotinylated hRFC proteins wt-mutant hRFC oligomers were still detected at the plasma membrane surface (Fig. 3B, lanes 3-5) . Although there are slight discrepancies between the levels of expression and the activity for wt hRFC in the S138C and G163P co-transfections, this was most pronounced for R373A-hRFC, for which there was no difference in levels of surface hRFC for either wt or mutant forms despite a disproportionately low level of transport activity.
Surface expression patterns for wt and mutant hRFCs in single or co-transfected R5 cells were confirmed by confocal microscopy and immunofluorescence staining with Alexa Fluor 488 (Myc) and Alexa Fluor 568 (HA)-conjugated secondary antibodies (Fig. 6) . Again, wt hRFC Myc-His10 and wt hRFC HA were both expressed at high levels at the cell surface either singly or in combination (panels a-e), consistent with our surface biotinylation results. There was no staining of untransfected R5 cells (not shown). As expected, for mutant hRFCs, surface fluorescence ranged from very low (S138C) to intermediate (G163P) and ultimately to the high levels approximating those for wt hRFC HA (R373A) (panels i, m, and q, respectively). In combined transfections with wt hRFC Myc-His10 , there was a slight (G163P) to significant (S138C) loss of green (wt) fluorescence (panels f and j, respectively). There was no obvious impact of R373A-hRFC HA on surface expression of wt hRFC (panel n).
Collectively, these results demonstrate the formation of oligomers between wt and mutant hRFCs that can be detected at the cell surface. For S138C-hRFC and (to a lesser extent) G163P-hRFC, there were losses of wt hRFC at the cell surface, to extents approximating those for the mutants. We hypothesize that this involves misfolding of mutant hRFC and retention in the ER such that mutant-wt oligomers experience the same fate. Analogous findings were reported for other transporters/channels including GlyT (29, 32) , hERG (30) , and the serotonin transporter (31) . Conversely, R373A-hRFC appears to exert a dominant-negative effect that impacts wt carrier function independent of effects on intracellular trafficking and surface expression.
wt hRFC Is Trapped Intracellularly in the Presence of Inactive Mutant S138C-hRFC-To explore the basis for the loss of surface wt hRFC in the presence of the S138C-hRFC mutant, we compared surface expression and intracellular trapping of wt hRFC in the presence and absence of S138C-hRFC by confocal microscopy. We modified our previous protocol to include Myc-tagged (wt) and HA-tagged (wt and S138C) hRFC proteins transiently expressed in R5 cells, and stained with anti-Myc rabbit or anti-HA goat antibodies and Alexa Fluor 568 (donkey anti-rabbit or donkey anti-goat, respectively) secondary antibodies. To simultaneously localize the ER with the hRFC forms, we used an ER membrane marker, protein disulfide isomerase, and anti-protein disulfide isomerase mouse anti- body with Alexa Fluor 488 (donkey anti-mouse) secondary antibody. Untransfected R5 cells were used as negative controls.
Both Myc-His 10 -and HA-tagged wt hRFC proteins individually (not shown) or in co-transfections (Fig. 7 , panels a-c and d-f) were expressed at high levels at the cell surface with insignificant intracellular staining. No staining was detected for untransfected R5 cells (not shown). Conversely, for S138C-hRFC HA , either alone or in combination with wt hRFC Myc-His10 , a very low level of mutant protein was targeted to the cell surface (panels i and l) as in our co-localization experiments (Fig.  6) . Rather, significant S138C-hRFC HA appeared to be trapped intracellularly, at least in part in association with the ER. wt hRFC Myc-His10 co-expressed with S138C-hRFC HA was also retained intracellularly, although there was a low level of detectable cell surface protein, as well (Fig. 7, panels m-o) .
These results are entirely consistent with the capacity of wt and S138C-hRFC proteins to oligomerize. S138C-hRFC may be not properly folded. Thus, it may not pass the ER quality control system and is retained intracellularly rather than trafficking to the plasma membrane. In the presence of a mutant hRFC such as S138C, both wt and mutant proteins are retained intracellularly, resulting in a substantial loss of wt carrier protein at the cell surface and decreased transport function.
Conclusions-In summary, the present study documents the existence of higher order homo-oligomers for hRFC, the major membrane transporter of folates and antifolates in mammalian cells and tissues (3, 4) . HA-and Myc epitope-tagged hRFC proteins were immunoprecipitated from both membrane particulate and surface-enriched membrane fractions from HeLa R5 transfectants, providing unambiguous evidence that oligomeric hRFC is expressed at the plasma membrane surface where it mediates internalization of folate co-factors and cytotoxic antifolates. By co-expression of wt and inactive mutant S138C hRFCs, a dominant-negative phenotype was demonstrated involving greatly decreased surface expression of wt carrier because of impaired intracellular trafficking and apparent retention in the ER. This may involve an aberrant interaction between mutant hRFC with a chaperone protein such as calnexin (30) that affects processing of wt carrier and could be direct or indirect. For another mutant (R373A), expression of oligomeric wt-mutant hRFC was accompanied by a significant and disproportionate loss of wt activity unrelated to levels of surface carrier. Although the mechanism responsible for this effect is unclear (see below), by systematic site-directed mutagenesis, Arg 373 was strongly implicated in carrier function (47, 48) and may facilitate substrate binding via the carboxylate groups of folate substrates (49) .
The present results provide important new insights into hRFC structure; they also raise numerous questions and significant challenges. For instance, although hRFC species with molecular masses of hRFC homo-oligomers were clearly identified by chemical cross-linking in our study, the nature of the major hRFC structural unit (e.g. dimers, tetramers, etc.) is uncertain. Further, it not yet established whether oligomeric hRFC is composed of a single hRFC monomeric polypeptide wrapped around a central transmembrane "channel" such that there are multiple translocation pathways per oligomer or whether a single transmembrane pathway for each oligomer is formed by multiple monomeric hRFC molecules. Although our dominant-negative studies establish both a structural and functional interplay between hRFC monomers, it remains to be established whether monomeric hRFC can in any way mediate either facilitative or active transport by itself or whether a functional "coupling" between monomers (15) is somehow obligatory. Of course, other explanations are also possible. For instance, loss of wt hRFC function may also be due to a biosynthetic defect that results in misfolding and inactivation of wt monomer, separate from a direct functional coupling between monomer hRFC forms. Studies are underway to address these possibilities.
The existence of homo-oligomeric hRFC has additional significance, ranging from a potential role in antifolate resistance and the possibility of "dominant-negative" interactions between mutant and wt hRFCs that result in impaired function or intracellular retention to the possibility of modulating oligomeric carrier function or trafficking with small molecules that act as "pharmacologic chaperones" to promote intracellular trafficking and surface expression. These topics will be the subject of future reports.
